Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single Arm, Open Label Study of Treatment-Free Remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients After Achieving Sustained MR4.5 on Nilotinib

Trial Profile

A Phase II, Single Arm, Open Label Study of Treatment-Free Remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients After Achieving Sustained MR4.5 on Nilotinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ENESTop
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 01 Jul 2019 According to a Novartis media release, data from this trial were presented at the 24th Congress of the European Hematology Association (EHA) 2019.
    • 01 Jul 2019 Results presented in the Novartis media release.
    • 13 Jun 2019 Results presented in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top